Retatrutide's TRIUMPH-1 trial produced 28.3% average weight loss versus semaglutide's 15% in the STEP trials — nearly double. But one of these medications is available today and one isn't available at all. Here's the honest comparison.
Semaglutide activates a single hormone receptor: GLP-1. This single pathway drives appetite suppression, slows gastric emptying, and improves insulin sensitivity.
Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. The added glucagon receptor activation is the key difference — it increases energy expenditure and fat oxidation directly, on top of appetite suppression. This is why retatrutide's trial results have consistently exceeded both semaglutide and tirzepatide (which activates two receptors: GLP-1 and GIP).
| Factor | Retatrutide | Semaglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon (triple) | GLP-1 only (single) |
| Avg weight loss | 28.3% (12mg, 80wk) | ~15% (2.4mg) |
| FDA approval status | Not approved — Phase 3 | FDA approved since 2017/2021 |
| Legally available? | No — clinical trials only | Yes — brand and compounded |
| Safety data depth | Limited — trials ongoing | 7+ years real-world data |
| Cost if available | Unknown — not priced yet | ~$99/mo compounded |
| Realistic access date | Q1–Q2 2028 estimated | Available today |
Search interest in "retatrutide vs semaglutide" is extremely high right now — among the highest of any GLP-1-related query we track. That's understandable given the trial results. But the comparison is currently theoretical, not practical, for one critical reason: retatrutide cannot be legally purchased, prescribed, or compounded anywhere in the United States.
It remains in Phase 3 clinical trials (the TRIUMPH program). Eli Lilly has confirmed an NDA submission target of Q4 2026, which — following standard FDA review timelines — points to realistic approval in late 2027 to Q1 2028, with patient access likely Q1–Q2 2028 at the earliest. For the full breakdown of this timeline, see our retatrutide FDA approval guide.
If you're choosing between these two medications today, you're not actually choosing — semaglutide is your only legal option of the two. The retatrutide trial data is genuinely exciting and worth knowing about, but it shouldn't factor into your treatment decision right now beyond knowing what might be available in 18-24 months.
The more useful comparison today is semaglutide vs tirzepatide — both legally available, both with real safety track records. Tirzepatide's dual mechanism (GLP-1+GIP) produces results closer to retatrutide's territory (~22% average weight loss) while being accessible right now. See our full semaglutide vs tirzepatide comparison for the practical decision you can actually act on today.
Once approved (realistically 2028), retatrutide will likely follow the same pattern as tirzepatide before it: high brand-name pricing initially ($1,000+/month), followed by compounded versions becoming available at significantly lower cost once compounding pharmacies can legally produce it. If your goal is long-term cost-effective access, the same telehealth + compounding model that makes semaglutide and tirzepatide affordable today will likely apply to retatrutide once it clears FDA review.
DirectMeds offers physician-supervised compounded semaglutide from $99/mo and tirzepatide from $149/mo — both with real safety data and immediate access.
Check eligibility →Want the full FDA approval timeline, trial data, and safety information as it develops?
Read the full timeline →